RT info:eu-repo/semantics/article
T1 Aniridia and the ocular surface: Medical and surgical problems and solutions
A1 Álvarez de Toledo Elizalde, J.
A1 López García, S.
A1 Benítez del Castillo, J.M.
A1 Durán de la Colina, J.
A1 Gris Castejón, O.
A1 Celis Sánchez, J.
A1 Herreras Cantalapiedra, José María
K1 Congenital aniridia
K1 Keratopathy
K1 Limbal stem cell transplantation
K1 Keratoplasty
K1 Keratoprostheses
K1 Limbal stem cell culture
K1 Mesenchymal cell culture
K1 3201.09 Oftalmología
AB Congenital aniridia is a multisystemic genetic disease due to a mutation in PAX6 gene which severely affects the development and functionality of the human eyes. In patients affected by the mutation, aside from the absence or defects of iris tissue formation, abnormalities in position or opacities of the crystalline lens, macular hypoplasia, ocular surface disease is the main cause of visual loss and the deterioration of the quality of life of most patients. Limbal stem cell deficiency combined with tear film instability and secondary dry eye cause aniridic keratopathy which, in advanced stages, ends up in corneal opacification. In this paper, the actual knowledge about congenital aniridia keratopathy physiopathology and medical and surgical treatment options and their efficacy are discussed. Indications and results of topical treatments with artificial tears and blood-derivatives in its initial stages, and different surgical techniques as limbal stem cell transplantation, keratoplasty and keratoprostheses are reviewed. Finally, recent advances and results in regenerative medicine techniques with ex vivo stem cell cultivation or other types of cultivated cells are presented.
PB Elsevier
SN 2173-5794
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/82872
UL https://uvadoc.uva.es/handle/10324/82872
LA eng
NO Álvarez de Toledo Elizalde J, López García S, Benítez Del Castillo JM, Durán de la Colina J, Gris Castejón O, Celis Sánchez J, Herreras Cantalapiedra JM. Aniridia and the ocular surface: Medical and surgical problems and solutions. Arch Soc Esp Oftalmol (Engl Ed). 2021 Nov;96 Suppl 1:15-37. doi: 10.1016/j.oftale.2021.04.003.
NO Producción Científica
DS UVaDOC
RD 19-feb-2026